| New class of anticholesterol drugs lowers LDL by 50% |
|
| Huffingtonpost: Three studies of Amgen Inc.'s version of these drugs, called evolocumab (ev-oh-LOKE-you-mab), found it lowered LDL or "bad" cholesterol by 55 to 66 percent compared to a fake drug, and by nearly that much when compared to Merck's Zetia, another cholesterol medication. |